Hormone receptor status rather than HER2 status is significantly associated with increased Ki-67 and p53 expression in triple-negative breast carcinomas, and high expression of Ki-67 but not p53 is significantly associated with axillary nodal metastasis in triple-negative and high-grade non-triple-negative breast carcinomas

American Journal of Clinical Pathology

Volumn 135, Issue 2, 2011, Pages 230-237

  Han, Jeong S ^a   Cao, Dengfeng ^b   Molberg, Kyle H ^a   Sarode, Venetia R ^a   Rao, Roshni ^a   Sutton, Lisa M ^a   Peng, Yan ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Axillary nodal metastasis; Breast cancer; Ki 67; P53; Triple negative

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; KI 67 ANTIGEN; PROTEIN P53; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER STAGING; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CARCINOMA; BIOSYNTHESIS; BREAST TUMOR; FEMALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY;

BREAST NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79952274160     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP9DV3EVZUATFV     Document Type: Article

References (30)

1. Hanby AM. Aspects of molecular phenotype and its correlations with breast cancer behaviour and taxonomy. Br J Cancer. 2005;92:613-617. (Pubitemid 40460591)
2. Nicolini A, Carpi A, Tarro G. Biomolecular markers of breast cancer. Front Biosci. 2006;11:1818-1843. (Pubitemid 43253397)
3. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
4. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-10874. (Pubitemid 32878711)
5. Kaplan HG, Malmgren JA. Impact of triple negative phenotype on breast cancer prognosis. Breast J. 2008;14:456-463.
6. Jones RL, Salter J, A'Hern R, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2009;116:53-68.
7. Gonzalez-Vela MC, Garijo MF, Fernandez F, et al. MIB1 proliferation index in breast infiltrating carcinoma: comparison with other proliferative markers and association with new biological prognostic factors. Histol Histopathol. 2001;16:399-406. (Pubitemid 32297637)
8. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25-32. (Pubitemid 46120191)
9. Petit T, Wilt M, Velten M, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer. 2004;40:205-211. (Pubitemid 38077022)
10. Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008;10:R65. doi:10.1186/bcr2124.
11. Lacroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer. 2006;13:293-325. (Pubitemid 43886660)
12. Lane DP. Cancer: p53, guardian of the genome. Nature. 1992;358:15-16.
13. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell. 1992;70:523-526.
14. Bidard FC, Matthieu MC, Chollet P, et al. p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Ann Oncol. 2008;19:1261-1265. (Pubitemid 351916575)
15. Tan DS, Marchio C, Jones RL, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat. 2008;111:27-44. (Pubitemid 352009225)
16. Rhee J, Han SW, Oh DY, et al. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer. 2008;8:307. doi:10.1186/1471-2407-8-307.
17. Molino A, Micciolo R, Turazza M, et al. Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. Int J Cancer. 1997;74:433-437. (Pubitemid 27400164)
18. Moriki T, Takahashi T, Kataoka H, et al. Proliferation marker MIB-1 correlates well with proliferative activity evaluated by BrdU in breast cancer: an immunohistochemical study including correlation with PCNA, p53, c-erbB-2 and estrogen receptor status. Pathol Int. 1996;46:953-961.
19. Spyratos F, Ferrero-Pous M, Trassard M, et al. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer. 2002;94:2151-2159. (Pubitemid 34411971)
20. Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99:167-170.
21. Sharma S, Saboorian HM, Frawley WH, et al. MIB1 labeling index as an indicator of chemoresponse in carcinoma of the breast. Appl Immunohistochem Mol Morphol. 2004;12:290-295. (Pubitemid 39602067)
22. Tewari M, Krishnamurthy A, Shukla HS. Predictive markers of response to neoadjuvant chemotherapy in breast cancer. Surg Oncol. 2008;17:301-311.
23. Cianfrocca M, Gradishar W. New molecular classifications of breast cancer. CA Cancer J Clin. 2009;59:303-313.
24. Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review [published online ahead of print November 23, 2009]. J Clin Oncol. 2010;28:92-98.
25. Marrelli D, Pinto E, Neri A, et al. Mib-1 proliferation index is an independent predictor of lymph node metastasis in invasive breast cancer: a prospective study on 675 patients. Oncol Rep. 2006;15:425-429.
26. Susini T, Nori J, Olivieri S, et al. Predicting the status of axillary lymph nodes in breast cancer: a multiparameter approach including axillary ultrasound scanning. Breast. 2009;18:103-108.
27. Erdem O, Dursun A, Coskun U, et al. The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma. Tumori. 2005;91:46-52. (Pubitemid 40469387)
28. Bosari S, Lee AK, Viale G, et al. Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up. Virchows Arch A Pathol Anat Histopathol. 1992;421:291-295.
29. Norberg T, Lennerstrand J, Inganas M, et al. Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors. Int J Cancer. 1998;79:376-383. (Pubitemid 28359736)
30. Hohenstein P, Giles RH. BRCA1: a scaffold for p53 response? Trends Genet. 2003;19:489-494. (Pubitemid 37101089)